ValiRx Plc (VAL) Receives “Speculative Buy” Rating from Beaufort Securities

Beaufort Securities reissued their speculative buy rating on shares of ValiRx Plc (LON:VAL) in a report issued on Monday, May 8th. The brokerage currently has a GBX 6.50 ($0.08) price objective on the stock.

WARNING: “ValiRx Plc (VAL) Receives “Speculative Buy” Rating from Beaufort Securities” was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at

ValiRx Plc Company Profile

ValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It operates in two business segments: drug development and the sale of self-test drug kits.

Receive News & Ratings for ValiRx Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx Plc and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply